AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Compare CAR-T CDMOs in USA
Compare Cell Therapy CDMOs in USA
Compare AAV CDMOs in USA
Compare Lentiviral CDMOs in USA
Compare ADC CDMOs in USA
Compare Recombinant Proteins CDMOs in USA
2 confirmed programs
· 1 sponsors
· Last scored 2026-11-02
79.9
Signal Score
✓ FDA Inspections (4)
✓ Clinical Trials (2)
○ SEC Filings
✓ Press (19)
✓ EMA GMP (27)
○ MHRA GMP
✓ HC GMP (11)
Quick Facts: AGC Biologics
- Signal Score
- 79.9/100 (as of 2026-11-02)
- Quality Compliance
- 99.8/100 — Clean EMA record: 27 active GMP certificates (no deductions)
- Headquarters
- Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
- Modalities
- CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
- Active Programs
- 2 confirmed from ClinicalTrials.gov across 1 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About AGC Biologics
3 approved commercial cell therapies.
Signal Score & Pillar Breakdown
Quality Compliance
99.8
Clean EMA record: 27 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Clean EMA record: 27 active GMP certificates (no deductions)
FDA Inspections4 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2026-05-29)
EMA GMP Certificates27 on record
Most Recent HC OutcomeCompliant · 2026-05-04
HC Attribution11 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 27 active GMP certificates (no deductions)
Operations
60.0
2 active programs across 1 sponsors
Modalities: Recombinant Protein, Monoclonal Antibody, Microbial Fermentation, AAV, CAR-T, ADC, Cell Therapy, Lentiviral
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
2 active programs across 1 sponsors · Modalities: Recombinant Protein, Monoclonal Antibody, Microbial Fermentation, AAV, CAR-T, ADC, Cell Therapy, Lentiviral · 2 programs in advanced phases (Phase 2/3)
Programs
2
Sponsors1
ModalitiesCAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
2 active programs across 1 sponsors
Modalities: Recombinant Protein, Monoclonal Antibody, Microbial Fermentation, AAV, CAR-T, ADC, Cell Therapy, Lentiviral
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
75.0
Strong parent backing: AGC Inc. (Japan)
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Strong parent backing: AGC Inc. (Japan)
Capacity
75.0
Multi-site operations (6 manufacturing sites)
Broad modality coverage (8 modalities)
Sites: Longmont, CO, Milan, Italy, Chiba, Japan, Heidelberg, Germany, Copenhagen (Søborg), Denmark, Bothell, WA
Source: company profiles (manufacturing sites, modality breadth)
6 manufacturing sites
StatusAvailable
Multi-site operations (6 manufacturing sites)
Broad modality coverage (8 modalities)
Sites: Longmont, CO, Milan, Italy, Chiba, Japan, Heidelberg, Germany, Copenhagen (Søborg), Denmark, Bothell, WA
Press Signals19 articles (not scored)
Multi-site operations (6 manufacturing sites)
Broad modality coverage (8 modalities)
AGC Biologics FDA Inspection History
2026-05
2025-04
2023-06
2023-02
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2026-05-29 |
AGC Biologics, Inc.
Bothell, Washington
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2025-04-18 |
AGC Biologics, Inc.
Bothell, Washington
Facility-linked
|
Blood and Blood Products | Not posted | Voluntary Action Indicated (VAI) |
| 2023-06-29 |
AGC Biologics A/S
Soborg
Company-level
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
| 2023-02-10 |
AGC Biologics, Inc.
Bothell, Washington
Facility-linked
|
Drug Quality Assurance | Not posted | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
AGC Biologics EMA GMP Compliance 27 certificates
2026-05
2026-02
2026-02
2026-02
2026-02
2026-02
2026-02
2025-10
2025-05
2025-05
2025-03
2025-03
2024-08
2024-08
2023-06
2023-06
2023-06
2023-06
2022-02
2021-04
2021-04
2021-04
2021-04
2018-11
2018-11
2018-11
2018-11
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| IT/123/H/2026 | Agc Biologics S.p.A. | Italy | 2026-05-14 | COMPLIANT |
| DK IMP 10001472 | AGC Biologics A/S | Denmark | 2026-02-19 | COMPLIANT |
| DK H 10001471 | AGC Biologics A/S | Denmark | 2026-02-19 | COMPLIANT |
| DK H 10001485 | AGC Biologics A/S | Denmark | 2026-02-19 | COMPLIANT |
| DK API-H 10001475 | AGC Biologics A/S | Denmark | 2026-02-19 | COMPLIANT |
| DK H 10001473 | AGC Biologics A/S | Denmark | 2026-02-19 | COMPLIANT |
| DK IMP 10001474 | AGC Biologics A/S | Denmark | 2026-02-19 | COMPLIANT |
| IT/54/H/2026 | AGC Biologics S.p.A. | Italy | 2025-10-23 | COMPLIANT |
| DK H 10001274 | AGC Biologics A/S | Denmark | 2025-05-13 | COMPLIANT |
| DK IMP 10001275 | AGC Biologics A/S | Denmark | 2025-05-13 | COMPLIANT |
| DE_BW_01_GMP_2025_0203 | AGC Biologics GmbH | Germany | 2025-03-13 | COMPLIANT |
| DE_BW_01_GMP_2025_0077 | AGC Biologics GmbH | Germany | 2025-03-13 | COMPLIANT |
| DK H 10001033 | AGC Biologics A/S | Denmark | 2024-08-22 | COMPLIANT |
| DK IMP 10001034 | AGC Biologics A/S | Denmark | 2024-08-22 | COMPLIANT |
| DK H 10000841 | AGC Biologics A/S | Denmark | 2023-06-29 | COMPLIANT |
| DK API-H 10000840 | AGC Biologics A/S | Denmark | 2023-06-29 | COMPLIANT |
| DK H 10000842 | AGC Biologics A/S | Denmark | 2023-06-29 | COMPLIANT |
| DK IMP 10000843 | AGC Biologics A/S | Denmark | 2023-06-29 | COMPLIANT |
| DE_BW_01_GMP_2022_0053 | AGC Biologics GmbH | Germany | 2022-02-23 | COMPLIANT |
| DK H 10000195 | AGC Biologics A/S | Denmark | 2021-04-22 | COMPLIANT |
| DK IMP 10000196 | AGC Biologics A/S | Denmark | 2021-04-22 | COMPLIANT |
| DK API-H 10000194 | AGC Biologics A/S | Denmark | 2021-04-22 | COMPLIANT |
| DK H 10000244 | AGC Biologics A/S | Denmark | 2021-04-22 | COMPLIANT |
| DK API-H 00115019 | AGC Biologics A/S | Denmark | 2018-11-13 | COMPLIANT |
| DK H 00114919 | AGC Biologics A/S | Denmark | 2018-11-13 | COMPLIANT |
| DK H 00115019 | AGC Biologics A/S | Denmark | 2018-11-13 | COMPLIANT |
| DK IMP 00115019 | AGC Biologics A/S | Denmark | 2018-11-13 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
biologics, general (non-sterile) · 2 sites
- Soeborg, Denmark · AGC Biologics A/S — biologics, general (non-sterile) · valid to Aug 8, 2029
- Heidelberg, Germany · AGC Biologics GmbH — biologics · valid to Feb 1, 2027 renewal filed
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Clinical Activity 2 studies
NCT04097301
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
PHASE1/PHASE2
Terminated
NCT00483509
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by...
PHASE2
Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity 38 open roles Beta
From public job postings on AGC Biologics' careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
38
open roles
31
in manufacturing, quality, PD/MSAT, engineering or regulatory (82%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 1 new posting, 2 taken down.
By function
By site
Copenhagen Denmark
profile site
6 mfg/ops · 5 QA/QC · 2 PD/MSAT · 5 eng. · 2 other 20
6 mfg/ops · 5 QA/QC · 2 PD/MSAT · 5 eng. · 2 other 20
Heidelberg Germany
profile site
4 mfg/ops · 1 QA/QC · 2 PD/MSAT · 1 other 8
4 mfg/ops · 1 QA/QC · 2 PD/MSAT · 1 other 8
Bresso Italy
2 mfg/ops · 3 QA/QC 5
2 mfg/ops · 3 QA/QC 5
Bothell Washington USA
profile site
· 1 eng. · 2 other 3
· 1 eng. · 2 other 3
Remote US - MA
· 2 other 2
· 2 other 2
Modality words in job titles
Biologics (cell culture, USP/DSP)5
Latest postings
Quality Control Technician, Cellular Biology 1
Quality (QA / QC) · Bresso Italy
XMLNAME, AI, Data Solutions Engineer
Engineering & facilities · Copenhagen Denmark
Supervisor Night, Mammalian Manufacturing, Downstream
Manufacturing & operations · Copenhagen Denmark
Student Assistant, Quality Control
Quality (QA / QC) · Copenhagen Denmark
Senior Specialist, Accounts Payable
Other (finance, HR, IT, other) · Copenhagen Denmark
Manufacturing Supervisor, Buffer, Night Shift
Manufacturing & operations · Copenhagen Denmark
Compliance Engineer, Facility Compliance and Qualification
Engineering & facilities · Copenhagen Denmark
Analytical Methods Development Technician
Quality (QA / QC) · Bresso Italy
Student Assistant, Security Operations
Other (finance, HR, IT, other) · Copenhagen Denmark
QC Bioassay Scientist, Maternity cover
Quality (QA / QC) · Copenhagen Denmark
Equipment Engineer, Equipment Maintenance, Calibration
Engineering & facilities · Copenhagen Denmark
General Manager, Site Head, SEA
Other (finance, HR, IT, other) · Bothell Washington USA
Coverage: counted from AGC Biologics' own careers board.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
agcbio.wd5.myworkdayjobs.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Company Signals 19 articles
Company announcements, not verified evidence. They do not change any score.
Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing - Genetic Engineering and Biotechnology News
Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing Genetic Engineering and Biotechnology News
Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate - BioSpace
Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate BioSpace
Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate - GlobeNewswire
Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate GlobeNewswire
Novelty Nobility Expands Manufacturing Pact With AGC Biologics in Japan - Contract Pharma
Novelty Nobility Expands Manufacturing Pact With AGC Biologics in Japan Contract Pharma
AGC Biologics Expands Deal With Novelty Nobility For Antibody Production - Bernama
AGC Biologics Expands Deal With Novelty Nobility For Antibody Production Bernama
Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate - Indovizka.com
Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate Indovizka.com
AGC Biologics Honoured For Leadership In Regulatory, Quality Compliance - Bernama
AGC Biologics Honoured For Leadership In Regulatory, Quality Compliance Bernama
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance - riauone.com
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance riauone.com
AGC Biologics Honoured For Leadership In Regulatory, Quality Compliance - Bernama
AGC Biologics Honoured For Leadership In Regulatory, Quality Compliance Bernama
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance - GlobeNewswire
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance GlobeNewswire
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance - FinancialContent
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance FinancialContent
AGC Biologics to expand CDMO capabilities in Japan with new $350M Yokohama site - megaproject.com
AGC Biologics to expand CDMO capabilities in Japan with new $350M Yokohama site megaproject.com
AGC Biologics Expands Capacity at Berkeley, California Facility | Libero Quotidiano.it - Libero Quotidiano
AGC Biologics Expands Capacity at Berkeley, California Facility | Libero Quotidiano.it liberoquotidiano.it
AGC Biologics Expands Capacity at Berkeley, California Facility | Libero Quotidiano.it - Libero Quotidiano
AGC Biologics Expands Capacity at Berkeley, California Facility | Libero Quotidiano.it Libero Quotidiano
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics - Yahoo Finance UK
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics Yahoo Finance UK
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics - Yahoo Finance
Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players - AbbVie, Abzena, AGC Biologics, Boehringer Ingelheim, Corden Pharma, Glatt, Kaneka, Phlow, and Wuxi Biologics Yahoo Finance
AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America - The Joplin Globe
AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America The Joplin Globe
AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America - Business Wire
AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America Business Wire
AGC Biologics Seattle Site Receives Anvisa GMP Certification - Contract Pharma
AGC Biologics Seattle Site Receives Anvisa GMP Certification Contract Pharma
Frequently Asked Questions About AGC Biologics
How many FDA inspections does AGC Biologics have on record?
CDMO Signal tracks 4 FDA inspections for AGC Biologics, sourced from the FDA inspection database. See the full inspection history above.
Has AGC Biologics received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for AGC Biologics.
Does AGC Biologics hold EMA or MHRA GMP certificates?
CDMO Signal tracks 27 EMA GMP certificates for AGC Biologics.
How many clinical programs is AGC Biologics linked to?
AGC Biologics is associated with 2 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is AGC Biologics's CDMO Signal Score?
AGC Biologics has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating AGC Biologics for a manufacturing program?
Use the free AI matchmaker to compare AGC Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
Biovian
Turku, Finland
Signal Score: 79.4
AAV, Lentiviral, Microbial Fermentation, Recombinant Protein
Compare AGC Biologics with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.